BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER

The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MOORE NICOLA, SCHERER STEFAN, WILD NORBERT, PALLAUD CELINE, KLAUSE URSULA
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	MOORE NICOLA SCHERER STEFAN WILD NORBERT PALLAUD CELINE KLAUSE URSULA
description	The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2015352204A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2015352204A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2015352204A13</originalsourceid><addsrcrecordid>eNqNyk0KwjAQQOFuXIh6hwHXQn_sASZxQoNNpiRTFyKUInElWqj3R0EP4Orx4FtmF9UyH6BrMToEZdlhOFKIYDiAohNqe-4dKtDslPUolj1IQwE7S18lgVAceQE2oD4TBTR6TWGdLW7jfU6bX1fZ1pDoZpem55DmabymR3oNfSzzoq7qssz3WFT_qTd65jMp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER</title><source>esp@cenet</source><creator>MOORE NICOLA ; SCHERER STEFAN ; WILD NORBERT ; PALLAUD CELINE ; KLAUSE URSULA</creator><creatorcontrib>MOORE NICOLA ; SCHERER STEFAN ; WILD NORBERT ; PALLAUD CELINE ; KLAUSE URSULA</creatorcontrib><description>The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; TESTING</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151210&DB=EPODOC&CC=US&NR=2015352204A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151210&DB=EPODOC&CC=US&NR=2015352204A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MOORE NICOLA</creatorcontrib><creatorcontrib>SCHERER STEFAN</creatorcontrib><creatorcontrib>WILD NORBERT</creatorcontrib><creatorcontrib>PALLAUD CELINE</creatorcontrib><creatorcontrib>KLAUSE URSULA</creatorcontrib><title>BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER</title><description>The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyk0KwjAQQOFuXIh6hwHXQn_sASZxQoNNpiRTFyKUInElWqj3R0EP4Orx4FtmF9UyH6BrMToEZdlhOFKIYDiAohNqe-4dKtDslPUolj1IQwE7S18lgVAceQE2oD4TBTR6TWGdLW7jfU6bX1fZ1pDoZpem55DmabymR3oNfSzzoq7qssz3WFT_qTd65jMp</recordid><startdate>20151210</startdate><enddate>20151210</enddate><creator>MOORE NICOLA</creator><creator>SCHERER STEFAN</creator><creator>WILD NORBERT</creator><creator>PALLAUD CELINE</creator><creator>KLAUSE URSULA</creator><scope>EVB</scope></search><sort><creationdate>20151210</creationdate><title>BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER</title><author>MOORE NICOLA ; SCHERER STEFAN ; WILD NORBERT ; PALLAUD CELINE ; KLAUSE URSULA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2015352204A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2015</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>MOORE NICOLA</creatorcontrib><creatorcontrib>SCHERER STEFAN</creatorcontrib><creatorcontrib>WILD NORBERT</creatorcontrib><creatorcontrib>PALLAUD CELINE</creatorcontrib><creatorcontrib>KLAUSE URSULA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MOORE NICOLA</au><au>SCHERER STEFAN</au><au>WILD NORBERT</au><au>PALLAUD CELINE</au><au>KLAUSE URSULA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER</title><date>2015-12-10</date><risdate>2015</risdate><abstract>The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US2015352204A1
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES TESTING
title	BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T07%3A20%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MOORE%20NICOLA&rft.date=2015-12-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2015352204A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true